Joint Pain Injections Market (By Injection Type: Corticosteroid Injections, Hyaluronic Acid Injections, Platelet-Rich Plasma Injections, Others; By Joint Type: Knee and Ankle, Hip, Shoulder and Elbow, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Joint Pain Injections Market 

5.1. COVID-19 Landscape: Joint Pain Injections Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Joint Pain Injections Market, By Product

8.1. Joint Pain Injections Market, by Product Type, 2021-2030

8.1.1. Pre-filled injections

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Vials

8.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Joint Pain Injections Market, By Injection

9.1. Joint Pain Injections Market, by Injection, 2021-2030

9.1.1. Corticosteroid Injections

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Hyaluronic Acid Injections

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Platelet-rich Plasma Injections

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Placental tissue matrix (PTM) Injections

9.1.4.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Joint Pain Injections Market, By Joint Type 

10.1. Joint Pain Injections Market, by Joint Type, 2021-2030

10.1.1. Knee and Ankle

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Hip

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Shoulder and Elbow

10.1.3.1. Market Revenue and Forecast (2019-2030)

10.1.4. Spinal Joints

10.1.4.1. Market Revenue and Forecast (2019-2030)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Joint Pain Injections Market, By Distribution Type 

11.1. Joint Pain Injections Market, by Distribution Type, 2021-2030

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Forecast (2019-2030)

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Forecast (2019-2030)

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 12. Global Joint Pain Injections Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2019-2030)

12.1.2. Market Revenue and Forecast, by Injection (2019-2030)

12.1.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.1.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.1.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.1.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.1.6.2. Market Revenue and Forecast, by Injection (2019-2030)

12.1.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.2. Market Revenue and Forecast, by Injection (2019-2030)

12.2.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.2.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.2.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.6.2. Market Revenue and Forecast, by Injection (2019-2030)

12.2.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.7.2. Market Revenue and Forecast, by Injection (2019-2030)

12.2.7.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2019-2030)

12.2.8.2. Market Revenue and Forecast, by Injection (2019-2030)

12.2.8.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.2. Market Revenue and Forecast, by Injection (2019-2030)

12.3.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.3.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.3.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.6.2. Market Revenue and Forecast, by Injection (2019-2030)

12.3.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.7.2. Market Revenue and Forecast, by Injection (2019-2030)

12.3.7.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2019-2030)

12.3.8.2. Market Revenue and Forecast, by Injection (2019-2030)

12.3.8.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.2. Market Revenue and Forecast, by Injection (2019-2030)

12.4.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.4.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.4.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.6.2. Market Revenue and Forecast, by Injection (2019-2030)

12.4.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.7.2. Market Revenue and Forecast, by Injection (2019-2030)

12.4.7.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2019-2030)

12.4.8.2. Market Revenue and Forecast, by Injection (2019-2030)

12.4.8.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2019-2030)

12.5.5.2. Market Revenue and Forecast, by Injection (2019-2030)

12.5.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2019-2030)

12.5.6.2. Market Revenue and Forecast, by Injection (2019-2030)

12.5.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)

Chapter 13. Company Profiles

13.1. Online Pharmacies

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bioventus

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Ferring Pharmaceuticals Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Sanofi

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Zimmer Biomet Holdings Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Allergen Plc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Pfizer Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Chugai Pharmaceutical Co. Ltd

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. SEIKAGAKU Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Ferring B.V.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

PROCEED TO BUY

   USD 4500.00
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample